中超控股1月9日在互动平台飚速，公司暂无产品可应用于脑机接口。 ...

Market Performance - The three major A-share indices collectively rose, with the Shanghai Composite Index increasing by 0.3% to 4095.33 points, briefly surpassing 4100 points, marking the highest level since July 2015 [1] - The Shenzhen Component Index rose by 0.57%, while the ChiNext Index increased by 0.1%, and the North Star 50 Index gained 0.55% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 208.19 billion yuan, an increase of 30.04 billion yuan compared to the previous day, with over 2300 stocks rising across the market [1] Sector Performance - The small metals sector continued its upward trend, with companies like Yunnan Zhenye, Dongfang Tantalum, and Xiamen Tungsten hitting new highs [1] - The commercial aerospace concept saw a resurgence, with nearly 20 stocks, including Xusheng Group and Julisi, reaching their daily limit [1] - Sectors such as short drama games, military equipment, and oil and gas showed significant gains, while some stocks related to brain-computer interfaces and storage chips experienced adjustments [1]

凤凰网财经讯 1月9日，早盘市场冲高回落，沪指时隔10年盘中再度突破4100点。截至午间收盘，沪指 涨0.3%，深成指涨0.57%，创业板指涨0.1%。量能持续放大，沪深两市半日成交额2.06万亿，较上个交 易日放量2963亿。 | | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 *● | 咸新 | 张幅% | | 涨跌 涨跌家数 | | 总手 | 现手 金额 | | 上证指数 | 4095.33 | 0.30 | 12.35 | 1006/1245 | -0.03 | 4.85 7. | 7.49万 8513.51亿 | | 深证成指 | 14038.46 | 0.57 | 78.98 | 1211/1599 | -0.07 | 6.60亿 | 1506 1.21万亿 | | 北证50 | 1516.63 | 0.55 | 8.25 | 153/129 | -0.01 | 7747 | 1039 206.81亿 | | 创业板指 | 3305.48 | 0.10 | 3.17 | 610/749 | ...

截至目前，公司向该项目牵头单位及其主管部门提交了一套面向智能显示的脑机交互系统终端。该项目 后续的相关工作由项目牵头单位及其主管部门组织实施。该项目及公司参与的子课题，不会对公司生产 经营产生影响，公司目前没有与该项目相关的成熟产品，亦未形成销售收入。 消息面上，南京熊猫表示，公司关注到近期脑机接口概念引发市场广泛关注，公司参与了"面向智能显 示的高速率脑机交互技术研发"项目的子课题"基于脑机接口技术的多模态人机交互系统集成关键技术研 发"。公司参与的子课题属于非核心技术部分。 南京熊猫（600775）电子股份(00553)盘中跌超7%，截至发稿，跌3.89%，报6.17港元，成交额3.16亿港 元。 ...

截至目前，公司向该项目牵头单位及其主管部门提交了一套面向智能显示的脑机交互系统终端。该项目 后续的相关工作由项目牵头单位及其主管部门组织实施。该项目及公司参与的子课题，不会对公司生产 经营产生影响，公司目前没有与该项目相关的成熟产品，亦未形成销售收入。 消息面上，南京熊猫表示，公司关注到近期脑机接口概念引发市场广泛关注，公司参与了"面向智能显 示的高速率脑机交互技术研发"项目的子课题"基于脑机接口技术的多模态人机交互系统集成关键技术研 发"。公司参与的子课题属于非核心技术部分。 智通财经APP获悉，南京熊猫电子股份(00553)盘中跌超7%，截至发稿，跌3.89%，报6.17港元，成交额 3.16亿港元。 ...

Group 1 - The core viewpoint of the article highlights the increasing market and funding attention towards brain-computer interfaces (BCIs), which are seen as a cutting-edge technology with significant future industry potential [2] - The medical device index ETF (159898) has seen a net inflow of over 170 million yuan in the last four trading days, with a single-day inflow exceeding 116 million yuan on January 8, marking a new high in its scale [2] - The medical device index ETF (159898) includes approximately 24% of companies with substantial involvement in the BCI sector, making it a convenient and efficient tool for investment in this emerging field [2][3] Group 2 - BCIs are interdisciplinary technologies that integrate neuroscience, computer science, and medicine, enabling direct communication between the brain and external devices [4] - Current applications of BCI technology are primarily in medical rehabilitation, particularly for patients recovering from strokes and spinal cord injuries, with potential future applications in education, entertainment, and industry [4] - The BCI sector is expected to experience strong growth driven by simultaneous advancements in policy, industry, and technology, with significant milestones anticipated by 2026 [7] Group 3 - The domestic BCI "unicorn" company, Qiangnao Technology, recently completed approximately 2 billion yuan in financing, becoming the second-largest financing in the BCI field globally, following Neuralink [7] - The Chinese government is actively supporting the BCI industry through various policies, emphasizing its importance as a key development area in the new five-year plan [7] - Recent breakthroughs in domestic BCI technology include successful clinical trials of fully implanted, wireless BCI products, indicating rapid advancements in the field [9] Group 4 - China's BCI market size grew from approximately 1 billion yuan in 2020 to about 1.73 billion yuan in 2023, representing a 12.5% share of the global BCI market [10] - Different institutions have varying growth forecasts for the BCI industry, with estimates suggesting the global market could reach 7.63 billion USD by 2029 [11] - The global BCI market is projected to grow to approximately 12.4 billion USD by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [14] Group 5 - BCIs are considered a potential key catalyst for driving upward trends in the medical device sector, supported by innovation and policy backing [15] - The medical device index ETF (159898) tracks the entire A-share medical device sector, with a pure representation of the industry and a 24% inclusion of BCI concepts, making it suitable for capturing opportunities in this emerging market [15]

Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

Core Viewpoint - The stock of Prit (002324) has seen significant gains, reaching historical highs, with a notable increase of over 8% and trading volume exceeding 4 billion yuan. The company has experienced four consecutive trading limits from January 5 to January 8 [1] Group 1: Company Operations - The company announced that its current operational situation is normal, with no significant changes in the internal or external business environment [1] - There are no undisclosed major matters regarding the company after inquiries with management, controlling shareholders, and actual controllers [1] Group 2: Product Development - LCP products are core materials developed over many years, applicable across various industries, and are general-purpose rather than customized products [1] - The LCP film products are currently undergoing testing with downstream clients in the brain-computer interface field, but due to long certification cycles, no large-scale orders are expected in the short term, and they have not yet generated revenue in this area [1] - There is a possibility of certification failures during client validation of LCP film products, indicating potential market competition risks in the medium to long term [1] Group 3: Revenue Impact - The LCP fiber materials are supplying a leading domestic client for low-orbit satellite flexible solar wings, but the order volume is currently very small, accounting for less than 0.01% of the company's total annual revenue, with minimal short-term impact on performance [2] - There is no significant growth trend anticipated for this business segment, and medium to long-term market competition risks remain [2]

近日有媒体报道称，"杭州六小龙"之一的强脑科技完成约20亿元融资，在脑机接口领域创下除Neuralink 外的全球第二大融资纪录。1月8日，强脑科技表示："确实完成融资，相关细节请以公司正式发布的信 息为准。募集资金将用于全力加速脑机接口核心技术研发、极限工程突破、产品规模化、量产落地。" 蓝思科技（06613）早盘股价上涨9.24%，报28.86港元，成交额3.23亿港元。 港股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 蓝思科技此前在投资者互动平台表示，蓝思科技是强脑科技的战略投资者，独家承接了强脑科技核心硬 件模组的量产。2025年11月，蓝思与强脑科技共同向湖南省残联捐赠大批智能仿生四肢，核心模组均来 自蓝思产线。 同时，公司与北美大客户已有10年以上深度合作，是其一级核心供应商。公司凭借强脑 科技等项目积累的量产经验以及强大的精密制造能力，正积极争取合作。 ...

Group 1 - The core viewpoint of the article highlights that Innovation Medical has achieved a five-day consecutive limit-up trading, indicating strong market interest and momentum [1] - The stock reached a trading halt at 9:43 AM with a transaction volume of 4.293 billion yuan and a turnover rate of 30.37% [1] - The brain-computer interface concept continues to generate market enthusiasm, with Innovation Medical investing in cutting-edge technology through its affiliated companies [1] Group 2 - The affiliated company of Innovation Medical has collaborated with Huawei Ascend to launch AI medical products, further enhancing its market position [1] - The operational success of its elderly care facilities has contributed to the company's positive market perception and interest [1] - Multiple factors, including technological advancements and operational performance, have created a resonance of market interest around Innovation Medical [1]